What Is New - Vasculitis

Take a look at our 'What is new' highlights in Vasculitis!

February 2023

"Risk factors for serious infections in ANCA-associated vasculitis"


Severe infections in patients with AAVs are the leading cause of death within the first year of diagnosis, while risk factors are yet to be studied thoroughly. This study emphasizes on the importance of low-dose cycles of antibiotics in AAV-patients having received immunosuppressive therapy, showing that B-cell counts are markers for immunocompetence.

Interactive question

What do you believe would you vote as the most important finding of this study?

  1. Therapy scheme
  2. Predictors of infections
  3. B- and T-cell characteristics in severe infections

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

January 2023

"High risk of stroke in ANCA-associated vasculitis-a population-based study"


AAVs consist of autoimmune phenotypes characterized by inflammation of small blood vessels. Patients with AAV exhibit a higher rate of comorbidities than the general population, including cardiovascular events. This is the first time that stroke risk in AAV patients is thoroughly studied, along with possible predictors and outcomes.

Interactive question

What do you believe would be helpful for elucidating CVD risk in AAVs?

  1. Larger Cohorts

  2. Multidisciplinary studies

  3. Relative risk compared to other autoimmune entities?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

December 2022

"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial"


Giant Cell Arteritis (GCA) is the most prevalent form of systemic vasculitis in adults. Therapeutic choices for ensuring remission in GCA patients are few, thus novel treatments are needed. Preclinical research has implicated GM-CSF in pathophysiology of GCA and mavrilimumab is an efficient GM-CSF receptor antagonist. This study proves that this new therapeutic weapon leads patients with GCA to sustained remission.

Interactive question

What would like to read as the next steps in mavrilimumab-related research?

  1. Pathophysiogical mechanism

  2. Mavrilimumab vs Tocilizumab

  3. Other (please comment)

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

Coming in February 2023...

Watch this space!